Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673258 | 1.00 | KDM4E (1.00) | KDM4EMAPTALDH1A1CA12CA1 | |
| SCHEMBL2638095 | 0.89 | KDM4E (0.81) | KDM4EMAPTALDH1A1ACHEALOX15 | |
| SCHEMBL29530477 | 0.89 | KDM4E (0.81) | KDM4EMAPTALDH1A1ACHEALOX15 | |
| SCHEMBL29202153 | 0.89 | KDM4E (0.78) | KDM4EMAPTALDH1A1CA12CA1 | |
| Hydrochloric Acid SCHEMBL698487 | 0.88 | KDM4E (0.78) | KDM4EMAPTALDH1A1ACHEALOX15 | |
| SCHEMBL2730135 | 0.86 | KDM4E (0.76) | KDM4EMAPTALDH1A1CA12CA1 | |
| SCHEMBL29365830 | 0.86 | KDM4E (0.76) | KDM4EMAPTALDH1A1CA12CA1 | |
| SCHEMBL3096482 | 0.85 | MAPT (0.73) | KDM4EMAPTALDH1A1CA12CA1 | |
| SCHEMBL30011603 | 0.85 | KDM4E (0.73) | KDM4EMAPTALDH1A1CA12CA1 | |
| SCHEMBL28039955 | 0.85 | MAPT (0.73) | KDM4EMAPTALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115626889-B | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2024-04-30 | — | — | CN | claimed |
| CN-105189461-B | The dibasic 1- acyl groups -4- amino -1,2,3,4- tetrahydroquinoline derivatives of 2,3- and their purposes as bromine domain inhibitor | 葛兰素史克知识产权第二有限公司 | 2018-05-15 | — | — | CN | claimed |
| EP-2588458-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-08 | — | — | EP | claimed |
| EP-1585757-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-08-01 | — | — | EP | claimed |
| WO-2012001020-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-05 | — | — | WO | claimed |
| EP-1585757-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | claimed |
| US-7442793-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-28 | — | — | US | claimed |
| US-20070173542-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2007-07-26 | — | — | US | claimed |
| JP-2006516120-A | — | — | 2006-06-22 | — | — | JP | claimed |
| EP-1585757-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-19 | — | — | EP | claimed |
| WO-2005072733-A1 | DYARYLUREA COMPOUNDS AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | WO | claimed |
| US-20050176733-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | claimed |
| WO-2004052919-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | claimed |
| EP-4547247-A2 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| CN-112543764-B | Amide compound with BET proteolytic induction effect and medical application thereof | 田边三菱制药株式会社 | 2024-05-10 | — | — | CN | disclosed |
| WO-1995014697-A1 | HETEROCYCLIC ESTERS OF RAPAMYCIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-06-01 | — | — | WO | disclosed |
| US-5385909-A | Heterocyclic esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-31 | — | — | US | disclosed |
| US-5354753-A | Methotrexate derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0543997-A1 | NOVEL METHOTREXATE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | KDM4E 3885/4885MAPT 4762/4885ALDH1A1 183/4885 |
| US-20070173542-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | KDM4E 2591/4885MAPT 3716/4885ALDH1A1 4302/4885 |
| US-20050176733-A1 | Chk-1 inhibitors | CHEK1, CHEK2, CHKA | KDM4E 955/4885MAPT 3306/4885ALDH1A1 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.